Abstract Body

Background

Broadly neutralizing antibodies (bNAbs) are promising therapies against HIV-1 but require repeated infusions, limiting use in low- and middle-income countries with high HIV prevalence. The helper-dependent adenovirus (HDAd) gene therapy platform offers an accessible strategy for long-term therapeutic delivery with a one-time vector infusion. We developed the HDAd 6/3+ vector system to transduce nonhuman primate (NHP) hematopoietic stem cells (HSCs) in vivo to express the broadly neutralizing rhesus eCD4-Ig variant ‘eCD4Ig-Emm06,’ engineered for stability and potency.

Methods

HDAd-eCD4Ig-Emm06 vectors expressed eCD4Ig-Emm06, TPST2 for eCD4-Ig sulfation, mgmtP140K for in vivo selection, and transient CXCR4 expression for bone marrow homing. HDAd-control vectors omitted eCD4Ig-Emm06 and TPST2 transgenes. HDAd-SB vectors encoded the Sleeping Beauty transposase to mediate transgene integration. Rhesus macaques received HDAd-eCD4Ig-Emm06 (n=3) or HDAd-control (n=3). Following HSC mobilization with G-CSF and AMD3100, HDAd vectors were infused followed by two cycles of O6BG/BCNU selection. Twelve weeks later, animals underwent escalating intravenous challenges with SIVmac239 until infection was established.

Results

The HDAd 6/3+ platform achieved long-term eCD4-Ig-Emm06 expression that stabilized between 2.5 and 11 μg/mL at 6 months post-HDAd infusion (79- to 349-fold above the IC50). qPCR and flow cytometry assays confirmed that transduced HSCs differentiated into lymphoid (T and B cells) and myeloid (monocyte) lineages and trafficked to systemic tissues. To identify cellular sources of eCD4Ig-Emm06 secretion, splenocytes were sorted into subsets and cultured ex vivo, revealing B cells as the primary producers. eCD4Ig-Emm06 animals had significantly reduced splenic viral reservoirs, and the animal with the highest levels exhibited fewer founder viruses, delayed onset to viremia, lower plasma viral loads, and protection of CD4+CCR5+ T-cells.

Conclusions

This proof-of-concept study demonstrates that in vivo HSC gene modification with a single vector administration enables durable expression of eCD4Ig-Emm06 that reduces viral burden in an NHP challenge model with SIVmac239. HSC gene therapy efficiently generates modified B-cells and can serve as a platform for sustained B-cell-targeted therapies. These data validate our gene therapy approach as an accessible strategy for long-term in vivo therapeutic production, applicable to a range of biotherapeutics including bNAbs and HIV fusion inhibitors.

Table or Figure